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Summary
 
The T cell response to the 65-kD mycobacterial heat-shock protein (Bhsp65) has been impli-
cated in the pathogenesis of autoimmune arthritis. Adjuvant arthritis (AA) induced in the Lewis
rat (RT-1
 
l
 
) by injection of 
 
Mycobacterium tuberculosis
 
 serves as an experimental model for human
rheumatoid arthritis (RA). However, the immunological basis of regulation of acute AA, or of
susceptibility/resistance to AA is not known. We have defined the specificity of the prolifera-
tive T cell responses to Bhsp65 during the course of AA in the Lewis rat. During the early phase
of the disease (6–9 d after onset of AA), Lewis rats raised T cell responses to many determinants
within Bhsp65, spread throughout the molecule. Importantly, in the late phase of the disease
(8–10 wk after onset of AA), there was evidence for diversification of the T cell responses to-
ward Bhsp65 carboxy-terminal determinants (BCTD) (namely, 417–431, 441–455, 465–479,
513–527, and 521–535). Moreover, arthritic rats in the late phase of AA also raised vigorous T cell
responses to those carboxy-terminal determinants within self(rat) hsp65 (Rhsp65) that corre-
spond in position to the above BCTD. These results suggest that the observed diversification is
possibly triggered in vivo by induction of self(Rhsp65)-reactive T cells. Interestingly, another
strain of rat, the Wistar Kyoto (WKY/NHsd) rat (RT-1
 
l
 
), with the same major histocompati-
bility complex class II molecules as the Lewis rat, was found to be resistant to AA. In WKY rats,
vigorous responses to the BCTD, to which the Lewis rat responded only in the late phase of
AA, were observed very early, 10 d after injection of 
 
M. tuberculosis.
 
 Strikingly, pretreatment with
the peptides comprising the set of BCTD, but not its amino-terminal determinants, provided
significant protection to naive Lewis rats from subsequent induction of AA. Thus, T cell responses
to the BCTD are involved in regulating inflammatory arthritis in the Lewis rat and in confer-
ring resistance to AA in the WKY rat. These results have important implications in understand-
ing the pathogenesis of RA and in devising new immunotherapeutic strategies for this disease.
 
R
 
heumatoid arthritis (RA)
 
1
 
 is an autoimmune disease
of unknown etiology (1, 2). In the past several years,
considerable interest has been generated in the role of the
65-kD mycobacterial heat-shock protein (Bhsp65) in the
pathogenesis of autoimmune arthritis both in experimental
animals (3, 4) as well as in humans (5–7). In RA patients,
an association between T cell responses to Bhsp65 and
early stages of joint inflammation has been observed (8–10),
suggesting that Bhsp65-reactive T cell responses are in-
volved in the pathogenesis of this disease. Adjuvant arthritis
(AA) can be induced in the inbred Lewis rat after immuni-
zation with 
 
Mycobacterium tuberculosis
 
 in oil (11–13). The
disease can also be transferred to naive Lewis rats by T cell
lines reactive to peptide 180–188 of Bhsp65 (3, 14). Al-
though arthritic Lewis rats develop vigorous T cell re-
sponses to native Bhsp65 and to peptide 180–188 of
Bhsp65, neither of these is arthritogenic when injected in
protein or peptide form, respectively (15, 16). Interestingly,
pretreatment with Bhsp65 can protect naive Lewis rats from
development of arthritis upon subsequent immunization with
 
1
 
Abbreviations used in this paper:
 
 AA, adjuvant arthritis; BCTD, Bhsp65 car-
boxy-terminal determinants; Bhsp65, 65-kD mycobacterial heat-shock
protein; BNTD, Bhsp65 amino-terminal determinants; EAE, experimen-
tal autoimmune encephalomyelitis; HEL, hen eggwhite lysozyme;
IDDM, insulin-dependent diabetes mellitus; LNC, lymph node cells;
MBP, myelin basic protein; NOD, nonobese diabetic; PLP, proteolipid
protein; PPD, purified protein derivative; RA, rheumatoid arthritis;
RCTD, carboxy-terminal determinants of Rhsp65; Rhsp65, rat hsp65;
S.I., stimulation index; SPC, spleen cells.
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M. tuberculosis
 
 (4, 17), suggesting that Bhsp65 contains pro-
tective as well as disease-inducing determinants. T cell lines
specific for Bhsp65 have also been shown to protect against
AA (14, 18). Similarly, Lewis rats afflicted with AA are re-
sistant to reinduction of AA (13). Neither the mechanism
of natural regulation of the acute inflammatory phase of AA
nor the mechanism of protection from subsequent induc-
tion of AA is known. Likewise, the immunological basis of
susceptibility or resistance to AA of different rat strains has
not been revealed.
In the present study, we have defined the changing pat-
tern of specificity of the T cell responses of Lewis rats to
determinants within Bhsp65 during the course of AA. Ar-
thritic Lewis rats in the early and late phase of the disease
revealed distinct patterns of T cell responses to Bhsp65. Im-
portantly, with progression of the disease, there was evi-
dence for diversification of the T cell responses toward
Bhsp65 carboxy-terminal determinants (BCTD). (The phe-
nomenon of spreading of the T cell responses to new de-
terminants within an antigen, after priming with a single
determinant of the same antigen, has been previously de-
scribed as determinant spreading [19]. On the other hand,
we have termed the induction of T cell responses to new
determinants after priming with the whole, multideterminant
antigen as diversification [20, 21]). Moreover, arthritic Lewis
rats in the late phase of AA also raised significant responses to
certain carboxy-terminal determinants within self(rat) hsp65
(Rhsp65). (Rat hsp60 [22] has been referred to as rat hsp65
in this study to emphasize its relationship with Bhsp65.)
These self-determinants correspond in position precisely to
that of the BCTD, suggesting that diversification of re-
sponse to Bhsp65 observed in vitro, might be triggered in
vivo by self-hsp65. In contrast with AA-susceptible Lewis
rats, MHC class II–identical, Wistar Kyoto (WKY/NHsd 
 
5
 
WKY) rats (23, 24) were found to be resistant to induction
of AA after immunization with 
 
M. tuberculosis.
 
 In fact, 
 
M.
tuberculosis
 
-immunized WKY rats raised early and vigorous
responses to the BCTD to which the Lewis rats only re-
spond during the late phase of the disease. Pertinently, pre-
treatment of naive Lewis rats with peptides comprising the
BCTD, but not its amino-terminal determinants (BNTD),
induced significant protection from AA. These results sug-
gest that T cell responses to the BCTD are involved in reg-
ulation of acute inflammatory arthritis. Our study suggests
one of the immunological bases for natural regulation of
acute AA, and of protection (resistance) from development
of AA.
 
Materials and Methods
 
Animals.
 
Inbred Lewis (RT-1
 
l
 
) and Wistar Kyoto (WKY/
NHsd) (
 
5
 
WKY) (RT-1
 
l
 
) rats were obtained from Harlan Sprague-
Dawley (San Diego, CA). Male rats, 5–12-wk-old, were used for
the experiments. The handling of animals and all procedures per-
formed on them were done in compliance with the guidelines of
the UCLA Chancellor’s Animal Research Committee.
 
Antigens–Peptides.
 
Bhsp65 from 
 
Mycobacterium bovis
 
 (which is
identical to hsp65 of 
 
M. tuberculosis
 
) was obtained from the World
Health Organization through Dr. R. van der Zee. The peptides con-
taining amino acid sequences of the Bhsp65 or Rhsp65 (22, 25,
26; the National Biomedical Research Foundation data base) were
prepared by three methods: (
 
a
 
) A complete series of overlapping
peptides (15-mers with an overlap of 11 amino acid residues) span-
ning the entire sequence of Bhsp65 was obtained from Chiron Mi-
motopes (Clayton, Australia). The peptides were synthesized using
the multi-pin peptide synthesis technique using repeated cycles of
Fmoc deprotection and amino acid couplings (27). The proce-
dure had been modified so that the peptides could be cleaved
from the pins. The terminal amino group of each peptide was ace-
tylated, whereas diketopiperazine was attached at the carboxy ter-
minus. (
 
b
 
) Several peptides of Bhsp65 and Rhsp65 were synthe-
sized in the UCLA Peptide Core Laboratory directed by Dr. J.R.
Reeve, Jr., using a Multiple Peptide Synthesizer (Advanced Chem
Tech, 396 MPS, Louisville, KY) as described elsewhere (28). The
identity and purity of these peptides were determined by Fast
Atom Bombardment Mass Spectrometry at the UCLA Center for
Molecular and Medical Sciences Mass Spectrometry facility. (
 
c
 
)
Some peptides were obtained from Macromolecular Resources
(Colorado State University, Fort Collins, CO). These peptides
were synthesized according to the method described elsewhere
(29). Hen eggwhite lysozyme (HEL) peptide was synthesized ac-
cording to the method previously described (29).
 
Induction of Adjuvant Arthritis.
 
Inbred male Lewis rats were
anesthetized using Halothane (Halocarbon Laboratories, River
Edge,  NJ), and then immunized subcutaneously in a hind footpad
with 200 
 
m
 
l of 
 
M. tuberculosis
 
 H37Ra (Difco Laboratories, De-
troit, MI) (10 mg/ml) suspended in IFA (Difco) or in mineral oil
(Sigma Chemical Co., St Louis, MO). The bacteria were pow-
dered in a mortar and pestle before suspension in oil. Beginning
on day 7 after immunization, the rats were observed daily for
clinical signs of arthritis in three of their limbs, excluding the limb
in which immunization was performed. The severity of arthritis
was evaluated on the basis of erythema, swelling, and deformity
of the joint (30, 31), and graded on a scale of 0 to 4 as follows:
0 
 
5
 
 no erythema or swelling, 1 
 
5
 
 slight erythema or swelling of
the ankle or wrist, 2 
 
5
 
 moderate erythema and swelling at the
wrist or ankle, 3 
 
5
 
 moderate erythema and swelling at the wrist/
metacarpals or ankle/metatarsals, 4 
 
5
 
 severe erythema and swell-
ing of the forepaw or hindpaw (32, 33). Because only the three
uninjected limbs were evaluated, the maximum arthritic score for
any rat was 12.
 
Histopathological Examination of Arthritic Joints.
 
The experimental
or age- and sex-matched control rats were sacrificed under anes-
thesia. A hind or front leg was cut above the ankle or the wrist,
respectively, with the help of a bone cutter. For histopathological
examination, the skin from the entire limb was removed and the
limb was immersed in 10% buffered formalin phosphate (Fisher
Scientific, Fair Lawn, NJ) for fixation for at least 2 d before decal-
cification. After decalcification, the sections were cut with a cryo-
tome and then stained with hematoxylin and eosin. The stained
sections were studied under the microscope for histopathological
changes in the joints as previously described (32, 33).
 
Lymph Node and Splenic T Cell Proliferation Assay.
 
The drain-
ing lymph nodes of rats immunized subcutaneously with 
 
M. tuber-
culosis
 
 as described above, were removed and a single cell suspen-
sion prepared (29). The debris was allowed to settle, and the cells
in the supernatant were washed twice with HBSS (GIBCO BRL,
Gaithersburg, MD).These lymph node cells (LNC) were cultured
in flat-bottomed 96-well plates at 5 
 
3
 
 10
 
5
 
 cells/well in HL-1 se-
rum-free medium (Ventrex Laboratories, Inc., Portland, ME)
supplemented with 2 mM 
 
l
 
-glutamine, 100 U/ml penicillin G 
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sodium, and 100 
 
m
 
g/ml streptomycin sulphate, with or without
antigen. (Splenic T cell proliferation assays were performed as de-
scribed for LNC, except for plating SPC at a concentration of 6 
 
3
 
10
 
5
 
 cells/well). For the pin peptides, one or two wells were tested
per peptide. Tuberculin purified protein derivative (PPD) (Evans
Medical Limited, Horsham, England) was used at a final concen-
tration of 2,000 U/well as a positive control. 1 
 
m
 
Ci of [
 
3
 
H]thy-
midine (International Chemical and Nuclear, Irvine, CA) was
added per well for the last 18 h of a 5 d culture. The cells were
then harvested on a Printed Filtermat A glass fiber filter (Wallac
Oy, Turku, Finland) using a Micro Cell Harvester (Skatron In-
struments, Inc., Sterling, VA), and the incorporation of radioac-
tivity was assayed by liquid scintillation counting, using the LKB
1205 Betaplate counter. The results were expressed as either cpm
or stimulation index (S.I. 
 
5
 
 cpm with antigen/cpm with cells in
medium alone). For some repeat experiments, HL-1 medium sup-
plemented with 1% (vol/vol) heat-inactivated FCS (Gemini Bio-
Products, Inc., Calabasas, CA) or X-Vivo 10 serum-free medium
(Bio-Whittaker, Walkersville, MD) supplemented with 2% FCS
and/or 5 
 
3
 
 10
 
2
 
5
 
 M 2-mercaptoethanol (Sigma) was used in place
of HL-1 medium. In some of these assays, 2.5–4.5 
 
3
 
 10
 
5
 
 cells/
well were used instead of 5–6 
 
3
 
 10
 
5
 
 cells/well.
 
Results
 
Early and Late Arthritic Responses of Lewis Rats.
 
Lewis rats
were immunized subcutaneously in a hind footpad with 
 
M.
tuberculosis
 
 in oil, and from 7 d after immunization onwards,
were observed daily for clinical signs of arthritis. The in-
duction of arthritis was further confirmed by histopatho-
logical examination of joints as described in Materials and
Methods.
Two timepoints were chosen for study of proliferative T
cell responses to Bhsp65 of LNC of arthritic rats: 6–9 d
(early phase of AA) or 8–10 wk (late phase of AA) after on-
set of clinical signs of arthritis (see Materials and Methods).
The rationale for choosing days 6–9 was that once arthritis
is evident in the hind and fore paws, it is anticipated that
lymph nodes draining these limbs would contain Bhsp65-
sensitized T cells, which could be tested in a T cell prolifer-
ation assay (in a fashion similar to immunization of a naive
rat subcutaneously with an antigen emulsified in an adju-
vant, and then testing the draining LNC for proliferative
responses to that antigen). The choice of 8–10 wk was made
because rats usually successfully contain active inflamma-
tion in the joints by that time. The overall objective of test-
ing LNC in the early and late phases of AA was to deter-
mine the dynamics of T cell responses to Bhsp65 during the
course of disease.
 
Response of Lewis Rats to Bhsp65 in the Early Phase of
AA.
 
As evident from Fig. 1 
 
A
 
, during the early phase of
AA, draining LNC of rats raised proliferative T cell re-
sponses to several determinants within Bhsp65: 13–27, 33–
47, 113–127, 177–191, 189–203, 217–231, 257–271, 277–
291, 313–327, 357–371, 385–399, 453–467, and 485–499.
Because rats were immunized with 
 
M. tuberculosis
 
, the im-
munogenic determinants shown in Fig. 1 
 
A
 
 (and in Fig. 1 
 
B
 
)
represent the dominant and subdominant determinants within
Bhsp65. As discussed below, from the viewpoint of arthritis
induction, the dominant and subdominant determinants
within Bhsp65 are of utmost importance.
 
Response of Arthritic Lewis Rats to Bhsp65 in the Late Phase
of AA.
 
In another series of experiments, the LNC of ar-
thritic Lewis rats in the late phase of the disease were tested
in a proliferation assay using pin peptides of Bhsp65. The
results of one representative experiment using pooled LNC
from four rats are given in Fig. 1 
 
B.
 
 The predominant peaks
representing the dominant and subdominant determinants
within Bhsp65 were found to correspond to the following
peptides: 173–187, 179–193, 185–199, 217–231, 237–251,
257–271, 281–295, 309–323, 349–363, 389–403, 417–431,
441–455, 465–479, 489–503, 513–527, and 521–535.
Upon detailed comparison of the profiles of proliferative
T cell responses of LNC of arthritic Lewis rats in the early
Figure 1. Response of arthritic Lewis rats to Bhsp65 in the early (A)
and late (B) phases of AA. Inbred Lewis rats were immunized subcutane-
ously with M. tuberculosis in a hind footpad, and then observed for signs of
arthritis. 6–9 d (early phase; A) or 8–10 wk (late phase; B) after the ap-
pearance of clinical AA, rats were killed and their popliteal, inguinal, and
axillary LNC pooled together were tested in a proliferation assay. In each
group, LNC from four rats were pooled for testing with peptides. Over-
lapping pin peptides spanning the entire length of the Bhsp65 were used
for the in vitro recall response in the assay. Each peptide is identified by its
first amino acid residue. The results are expressed as cpm. The results of a
representative experiment using pooled LNC from four rats are shown in
each section of the figure. Similar results were obtained in repeat experi-
ments with pooled LNC or upon testing cells from individual rats with
selected Bhsp65 peptides (data not shown). In B, the T cell responses to
new, unique Bhsp65 carboxy-terminal determinants (BCTD) are indi-
cated by arrows. 
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and late phases of the disease (Fig. 1, Table 1), three note-
worthy findings were observed. First, Lewis rats in the late
phase of AA gave strong proliferative responses to several
new BCTD; namely, 417–431, 441–455, 465–479, 513–
527, and 521–535, compared with Lewis rats in the early
phase of AA. These BCTD had an average relative strength
(see Table 1 for description of this index) of 47.8% in the
late response in comparison to 13.0% in the early response.
Second, rats in the late phase of AA gave significantly de-
creased responses to certain BNTD; namely, 1–15, 13–27,
33–47, 113–127, and 121–135 compared with the pattern
of responses of rats in the early phase of the disease. The
average relative strength of these amino-terminal determi-
nants was 52% in the early response in comparison to 10%
in the late response (data not shown). Third, in general, the
level of the proliferative response to the middle region de-
terminants of Bhsp65 was much higher in the late phase of
the disease but essentially unchanged in pattern.
 
Lewis Rats in the Late Phase of AA Raise Significant T Cell
Responses to Carboxy-terminal Determinants within Self(rat)
hsp65 (Rhsp65).
 
To determine whether T cell responses
to new carboxy-terminal determinants observed in the late
phase of AA are restricted to Bhsp65 or also involve self(rat)
hsp65 (Rhsp65), spleen cells (SPC) of arthritic Lewis rats
(4 wk after onset of arthritis) were tested in a proliferation
assay using peptides containing those carboxy-terminal de-
terminants of Rhsp65 that correspond in position to the
BCTD to which T cell responses are diversified during the
late phase of AA (Table 2). The results given in Fig. 2 dem-
onstrate that arthritic Lewis rats raise vigorous T cell re-
sponses to the carboxy-terminal determinants of both Bhsp65
and Rhsp65. These results suggest that there is induction of
Rhsp65-reactive T cells in vivo during the course of AA.
 
WKY Rats, with the Same MHC Class II Haplotype as the
Lewis Rat, Are Resistant to AA.
 
To determine the role of
MHC versus non-MHC genes in determining susceptibil-
ity or resistance to AA, we tested the WKY rats, which are
of the same MHC class II haplotype as the Lewis rat (23,
24). Strikingly, under the same conditions used for induc-
tion of AA in the Lewis rat, age- and sex-matched WKY
rats were found to be resistant to AA. Only 3 out of 51
 
Table 1.
 
T Cell Responses of Arthritic Lewis Rat to the
COOH-terminal Determinants of Bhsp65
 
Peptide
Early phase of AA Late phase of AA
cpm 
 
3
 
 10
 
2
 
3
 
(S.I.)
 
Relative
strength
cpm 
 
3
 
 10
 
2
 
3
 
(S.I.)
 
Relative
strength
 
%%
 
417–431 6.4 (2.2) 11.9 55.9 (16.2) 36.8
441–455 4.6 (1.6) 8.6 84.0 (24.3) 55.3
465–479 8.0 (2.7) 14.8 97.3 (28.2) 64.2
513–527 3.9 (1.3) 7.3 72.4 (21.0) 47.7
521–535 12.1 (4.1) 22.6 53.5 (15.5) 35.3
Mean value 7.0 (2.4) 13.0 72.6 (21.0) 47.8
The T cell responses of arthritic Lewis rats to certain selected peptides
of Bhsp65 shown in Fig. 1 are expressed above in three ways: cpm (in a
 
b
 
-scintillation counter), stimulation index (S.I. 
 
5
 
 cpm with antigen/
cpm without antigen [cells in medium alone]) and relative strength (%)
(
 
5
 
 cpm with the particular peptide relative to the mean cpm of the
other four peaks in the pepscan of both the early and the late phase of
AA; the value was expressed as a percentage. To assure equivalent com-
parisons, the same four peaks were chosen as reference [100%] in the
early and late phases of AA). To attempt to express an overall index, the
average RS value for BCTD in early and late AA were calculated.
 
Table 2.
 
The Amino Acid Sequences of the Peptides Comprising 
the COOH-terminal Determinants of Bhsp65 and Rhsp65
 
Peptides Amino acid sequences
Bhsp 417–431
 
LLQAAPTLDELKLEG
 
Rhsp 418–432
 
--RCI-A--S--PAN
 
Bhsp 441–455
 
KVALEAPLKQIAFNS
 
Rhsp 441–455
 
II-R--KI-AMT--K
 
Bhsp 465–479
 
KVRNLPAGHGLNAQT
 
Rhsp 465–479
 
VE-ILQSSSEV-YD-
 
Bhsp 513–527
 
TT*EAVVADKPEKEKA
 
Rhsp 512–526
 
LL--A----TEI-*--
 
Bhsp 521–535
 
KPEKEKASV*PGGGDM
 
Rhsp 521–535
 
T-IP-EEKD--M-A-
 
2 5
 
 identical residue; * 5 gap introduced for best alignment.
Figure 2. Response of arthritic Lewis rats to peptides containing the
COOH-terminal determinants within Bhsp65 (A) or Rhsp65 (B). Arthri-
tis was induced as described in Materials and Methods. 4 wk after the ap-
pearance of clinical AA, rats were killed and their spleen cells (SPC) tested
in a proliferation assay. The results are expressed as cpm. The results of a
representative experiment are shown here. Similar results were obtained
in repeat experiments (data not shown). The amino acid sequences of the
five peptides comprising the BCTD and of the corresponding Rhsp65
peptides are given in Table 2. Response to peptide 177–191 is shown as a
positive control. Rhsp65 peptide 465–479 could not be tested in this se-
ries of experiments.1311 Moudgil et al.
(5.9%) WKY rats developed mild (grade 1) AA. The re-
maining WKY rats, observed for more than 18 mo, did not
manifest any clinical or histopathological signs of AA (data
not shown).
Early and Vigorous Response to the Carboxy-terminal Deter-
minants of Bhsp65 in AA-resistant WKY Rats after Immuniza-
tion with M. tuberculosis. To determine the immunological
basis of susceptibility/resistance to AA, we tested the T cell
responses of WKY rats to peptides of Bhsp65 following in-
jection of M. tuberculosis. Based on the results shown in Fig. 1,
we reasoned that susceptibility or resistance of rat strains of
the same MHC haplotype to AA might relate primarily to
differences in processing and presentation of Bhsp65: effi-
cient and earlier display of the BCTD would ensure pro-
tection from AA, whereas lack of or inefficient presentation
of these determinants would result in active disease. Alter-
natively, the resistance to AA of the WKY rat strain could
be owing to its inability to process and present the poten-
tially arthritogenic determinant 180–188 within Bhsp65.
The results given in Fig. 3 clearly demonstrate that 10 d
after immunization with M. tuberculosis, WKY rats raised
T cell responses to several determinants within Bhsp65. In-
terestingly, unlike Lewis rats in the early phase of AA (see
Fig. 1 A), WKY rats could raise significant T cell responses
to the BCTD; Lewis rats raised T cell responses to the
BCTD only in the late phase of AA (see Fig. 1 B). Although
the highest proliferative responses to Bhsp65 peptides in
the carboxy-terminal region correspond to peptides 421–
435, 445–459, 469–483, 517–531, and 525–539, WKY rats
also raised significant responses to the overlapping peptides
immediately preceding these peptides in the pepscan, namely,
417–431, 441–455, 465–479, 513–527, and 521–535 (Fig.
3). In repeat experiments, the proliferative responses to the
adjacent overlapping peptides comprising each of these five
pairs of peptides either was comparable or the pattern was
reversed compared with the above pattern (data not shown).
Importantly, WKY rats were not deficient in raising re-
sponses to peptide 177–191, which contains the minimal
arthritogenic determinant, 180–188, described for Lewis
rats (4), and is cross-reactive with it. These results suggest
that despite reactivity to a known (established) arthritoge-
nic determinant within Bhsp65, efficient T cell responses to
carboxy-terminal determinants of the same protein were
successful in affording protection to WKY rats from devel-
opment of AA.
Pretreatment of Naive Lewis Rats with Peptides Containing
the BCTD Afford Protection from AA. Finally, to determine
the physiologic role of diversification of T cell responses to
Bhsp65 in AA, we treated naive Lewis rats with an immu-
nogenic combination of five peptides containing the se-
quence of the BCTD. 5–6 wk later, these rats were then
challenged with M. tuberculosis in an attempt to induce AA,
and thereafter these rats were observed regularly for clinical
signs of AA. The results are given in Fig. 4 A. Strikingly,
pretreatment with the BCTD afforded significant protec-
tion to naive Lewis rats from subsequent induction of AA,
whereas age- and sex-matched control Lewis rats treated
with an irrelevant HEL peptide exhibited the usual course
of the disease. In comparison to control rats, BCTD-
treated rats developed much milder arthritis or not at all
and, eventually, did not reveal permanent joint deformities.
Similar results were obtained in two other similar experi-
ments (data not shown). On the contrary, in another series
of experiments in age- and sex-matched Lewis rats using
the same protocol except for injection of M. tuberculosis 2
wk (instead of 5–6 wk) after pretreatment with the BCTD,
there was no evidence of protection from AA (data not
shown). Thus, the duration of the period after pretreatment
with the BCTD is the most crucial factor in determining
the outcome of the interplay between the BCTD-specific
regulatory T cells and the arthritogenic T cells.
In another experiment, pretreatment of naive Lewis rats
with peptides comprising certain Bhsp65 amino-terminal de-
terminants (BNTD); namely, 13–27, 33–47, and 121–135,
was performed to determine whether peptides from a region
other than the carboxy-terminal region of Bhsp65 have any
effect on the outcome of AA. The conditions of this exper-
iment were similar to that of the above experiment using
pretreatment with BCTD. The control HEL peptide used
in the two experiments also was the same. The results of
the experiment given in Fig. 4 B show that the course of
AA in BNTD-treated rats was similar to that of the age-
and sex-matched HEL peptide-treated rats. Furthermore,
both these groups of rats exhibited disease characteristics
similar to that of the control group of HEL peptide-treated
rats shown in Fig. 4 A. These results demonstrate that the
protective effect of Bhsp65 peptides against AA is simply
not a general property of just any region of Bhsp65; as
shown above, the carboxy-terminal, but not the amino-
terminal peptides of Bhsp65 were protective against AA.
Figure 3. Response of AA-resistant Wistar Kyoto (WKY) rats to
Bhsp65 peptides after injection of M. tuberculosis. Rats were immunized
with M. tuberculosis subcutaneously and after 10 d, the draining LNC from
four rats were pooled and tested in a proliferation assay as described in
Fig. 1. The results are expressed as cpm. The T cell responses to the
unique carboxy-terminal determinants of Bhsp65 (to which arthritic Lewis
rats respond only in the late phase of AA; shown in Fig. 1 B) are indicated
by arrows. Although the highest proliferative responses correspond to the
peptides marked by arrows, comparable or even higher responses also
were raised to the adjacent overlapping peptides; namely, 417–431, 441–
455, 465–479, 513–527, and 521–535 in repeat experiments (data not
shown). Responses to the BCTD were observed in repeat experiments in
WKY rats tested 10–13 d after M. tuberculosis injection (data not shown).1312 Responses to the 65-kD Heat-Shock Protein of Lewis and Wistar Kyoto Rats
In summary, the above results demonstrate that induc-
tion of T cell responses to the BCTD are involved in pro-
viding protection from subsequent induction of AA and,
thereby, are also capable of inducing natural regression of
acute inflammatory arthritis in vivo.
Discussion
The phenomenon of broadening of the T cell response
to other determinants within a particular native antigen, af-
ter induction of disease with only a single determinant of
the same antigen has previously been described as determi-
nant spreading (19). In this study, we observed a shift in the
specificity of T cell responses to new determinants within
Bhsp65 after priming with the whole multideterminant an-
tigen (native Bhsp65 as a component of M. tuberculosis), and
have termed this diversification of the T cell response (20,
21). Determinant spreading has previously been reported in
the diseases murine experimental autoimmune encephalomy-
elitis (EAE) and insulin-dependent diabetes mellitus (IDDM)
(19, 34). In the case of EAE, the disease was induced by a
self-peptide, Ac1-11, of myelin basic protein (MBP), but dur-
ing the course of the disease, the T cell response spread to
other determinants within MBP, and in other studies (35,
36), to determinants on proteolipid protein (PLP) by inter-
molecular spreading. Likewise, in the case of spontaneously
developed IDDM, there was evidence for both intramolec-
ular (within glutamic acid decarboxylase; GAD65) and in-
termolecular (to determinants of hsp65, carboxypeptidase
H, and insulin) determinant spreading (34). The novel fea-
tures of our study on diversification of the T cell response
in AA compared with the above two examples are the fol-
lowing: first, the observed diversification involved determi-
nants within a foreign (mycobacterial) antigen, Bhsp65;
second, both in EAE and IDDM, determinant spreading
was implicated in perpetuation of the autoimmune re-
sponse, whereas in our study we demonstrate that diversifi-
cation of the T cell response to the carboxy-terminal deter-
minants of Bhsp65 is involved in inducing regulation of
inflammatory arthritis or protection from arthritis (regula-
tory diversification) in the AA-susceptible Lewis or the
AA-resistant WKY rat strains, respectively. Furthermore, our
results suggest that this diversification might be accentuated
by determinants within self(rat) hsp65. In this regard, our
study extends a novel dimension to the functional signifi-
cance of diversification of T cell response in autoimmunity.
Here, we describe diversification of T cell responses during
the course of an autoimmune disease induced by a foreign
antigen. In addition, this model offers us a unique opportu-
nity to analyze relationships between the T cell repertoires
directed against pathogenic foreign antigen and the homol-
ogous self-antigen. We believe that the principles eluci-
dated in this study are widely applicable to several autoim-
mune situations in which autoreactivity is induced by
molecular mimicry (29, 37, 37a) between a foreign and a self-
antigen. Immediate and direct application of this knowledge
would be in those autoimmune diseases (e.g., diabetes, Beh-
Figure 4. Pretreatment of naive Lewis rats with peptides comprising
the BCTD afford protection from subsequent induction of AA. One
group of 5–6-wk-old Lewis rats (n 5 9) was immunized subcutaneously
with a combination of five Bhsp65 peptides (namely, 417–431, 441–455,
465–479, 513–527, and 521–535) (A) mixed in N,N-Dimethyl-N,N-
dioctadecyl ammonium chloride (DDA) (GERBU adjuvant; GERBU
Biotechnik GmbH, Gaiberg, Germany) (17, 55). Each rat received 100
mg of each of the five peptides mixed together in the same suspension.
Another group of age- and sex-matched control Lewis rats (n 5 6) was
immunized with HEL peptide 85–96/DDA. After 5 wk, these rats were
immunized subcutaneously with M. tuberculosis for induction of AA.
From 7 d onwards, rats were examined daily or on alternate days for signs
of arthritis. The severity of arthritis in each of the three uninjected paws
was graded on a scale from 0 to 4 as described in Materials and Methods,
and the highest score achievable in any rat was 12 (32, 33). Rats were ob-
served for up to 61 d after injection of M. tuberculosis. The difference be-
tween the arthritic score (mean 6 SEM) of experimental (s) and control
rats (d) from day 10 through day 47 (after M. tuberculosis injection) was
found to be statistically significant (e.g., day 12, P ,0.05; day 17, P ,0.01;
day 25, P ,0.01; day 34, P ,0.01, and day 47, P ,0.001, all by Student’s
t test. The results of the two groups of rat were also statistically significant
when analyzed by nonparametric, Wilcoxon-ranked sum test). Another
group of Lewis rats (n 5 6) (h) was immunized subcutaneously with a
combination of three Bhsp65 amino-terminal peptides (namely, 13–27,
33–47, and 121–135) (B) mixed in DDA. The control group (n 5 5) (j)
was immunized with HEL peptide 85–96/DDA. The conditions of the
experiment were similar to those of the experiment shown in A. Rats
were examined for up to 60 d after injection of M. tuberculosis. The differ-
ence between the two groups of rats was not statistically significant at any
of the timepoints tested.1313 Moudgil et al.
cet’s disease, multiple sclerosis) that might be induced/per-
petuated by heat-shock proteins.
In this study, we observed that in the late phase of arthri-
tis in the Lewis rat there was diversification of the T cell re-
sponses to include new determinants within the Bhsp65.
T cell responses to the BCTD were evident even at 4 wk
after onset of AA. Moreover, results of the experiments
employing pretreatment with peptides comprising the BCTD
clearly demonstrate that BCTD-reactive T cells are indeed
responsible for inducing significant regression of acute in-
flammatory arthritis in the Lewis rat, presumably by down-
regulating the activity of disease-inducing effector T cells.
Furthermore, the protective effect against AA is not simply
a property of peptides derived from any region of Bhsp65;
in this study, pretreatment with BCTD but not BNTD
brought about protection from subsequent induction of AA.
However, the timing of pretreatment with BCTD is a crit-
ical factor in determining the final outcome; significant
protection from AA in Lewis rats is only achieved if pre-
treatment is done 5–6 wk before injection of M. tuberculo-
sis; pretreatment 2 wk before induction of AA has no effect
on the course of the disease. These results suggest that the
appearance of, and manifestation of the effect of, regulatory
T cells either during the course of AA or after pretreatment
of naive Lewis rats with the BCTD apparently requires 4–6
wk of time. Interestingly, it had been reported earlier that
pretreatment of naive Lewis rats with native Bhsp65 or
with peptide 180–188 of Bhsp65 induced protection from
subsequent induction of AA; again, the protective effect of
Bhsp65 or of peptide 180–188 was observed when these
antigens were administered 5 wk before induction of AA
(4, 16). At this time, we do not know how pretreatment
with the BCTD affords protection from AA. It is conceiv-
able that the activity of arthritogenic T cells can be con-
trolled either by cytokines (e.g., by induction of Th2 cells)
or through a TCR-centered idiotypic circuit (38). Consider-
ing that peptide 180–188 (16) or peptide 256–270 (39) of
Bhsp65 also can afford protection from AA, we suggest that
protection against AA induced by pretreatment either with
peptide 180–188 or 256–270, or by the BCTD might be
mediated through parallel or, conceivably, a final common
pathway of regulation. The precise mechanisms underlying
this regulation are currently under investigation. Consider-
ing the size of Bhsp65, it is feasible that different regions of
the same molecule are protective, and that this degeneracy
in regulation (or multilayered regulation) might be of evo-
lutionary advantage. Additional support for similar redun-
dant regulatory pathways derives from studies using the
nonobese diabetic (NOD) mouse: diabetes in this mouse
strain can be modulated by administration of any one of
several defined antigens (reviewed in reference 40).
The diversification of T cell responses to the carboxy-
terminal determinants of hsp65 during the course of AA
could be attributed to enhanced processing and presenta-
tion of Bhsp65 and/or Rhsp65 under the inflammatory
conditions (41–43) prevalent during acute AA (Fig. 5). Our
results shown in Figs. 2 and 4 suggest that the T cell reper-
toire shared between Bhsp65 and Rhsp65 is involved in di-
versification of the response as well as in regulation of AA.
Thus, the induction of RCTD-reactive T cells in vivo, and
their recruitment by cross-reactive BCTD might be a ma-
jor mechanism underlying the observed diversification of
the T cell response to the COOH-terminal determinants of
Bhsp65 (Fig. 5, scheme b). However, it is possible that both
mechanisms shown in Fig. 5 might operate simultaneously,
and that T cell responses to BCTD as well as RCTD could
arise even in the absence of significant cross-reactivity be-
tween BCTD and RCTD. Which of the above mecha-
nisms is (are) actually involved in the diversification of the
T cell response to BCTD and in natural regulation of AA is
the subject of current investigations.
In comparison to our results shown in Fig. 1, Anderton
et al. (17) (a) observed proliferative responses to relatively
fewer dominant/subdominant determinants of Bhsp65 after
immunization of Lewis rat with Bhsp65. We believe that
these differences are primarily owing to lower sensitivity
under their immunization and assay conditions, as well as
to possibly subtle differences in the inherent responsiveness
of the rat strains used from different sources, as has been re-
ported in the case of EAE (44); (b) did not find any change
in the pattern of reactivity at different timepoints after im-
munization with native Bhsp65. Our interpretation of
Figure 5. A schematic representation of the proposed mechanisms of diver-
sification of T cell responses to the COOH-terminal determinants of hsp65:
(a) The Bhsp65 diversification pathway: enhanced processing of Bhsp65
under the inflammatory milieu raised in acute AA, leading to induction of
a diversified T cell response to BCTD. These BCTD-reactive T cells,
which include BCTD-specific and BCTD/RCTD-cross-reactive T cells,
then regulate the activity of arthritogenic T cells. (b) The Rhsp65 inter-
molecular spreading pathway: upregulation of antigen processing during
acute AA induced by M. tuberculosis results in induction of T cell responses to
the COOH-terminal determinants of Rhsp65 (RCTD) through mecha-
nisms of intermolecular and intramolecular determinant spreading (34,
41). Some of these self-hsp65 responses are regulatory from both RCTD-
specific as well as RCTD/BCTD-cross-reactive T cells and bring about
natural remission from acute AA. Induction of response to Rhsp65 in
turn can initiate intermolecular spreading to determinants within Bhsp65.1314 Responses to the 65-kD Heat-Shock Protein of Lewis and Wistar Kyoto Rats
these results is that because immunization with Bhsp65
(mixed in the adjuvant, DDA) did not cause AA, the requi-
site conditions for diversification of T cell responses to
Bhsp65 simply did not exist.
We observed that coupled with the diversification of T
cell response during the course of AA in the Lewis rat, the
proliferative T cell responses to certain BNTD were signif-
icantly downmodulated in the late phase of the disease. At
this time, we do not know whether downmodulation of
responses to BNTD has any physiologic significance. One
possibility is that besides the arthritogenic determinant
180–188, the BNTD also might be contributing to induc-
tion/perpetuation of arthritis in the Lewis rat and, there-
fore, to contain the autoimmune reactivity, the responses
to these determinants must be downregulated.
We have observed that the WKY rat, with the same
MHC class II molecules as the Lewis rat, is resistant to AA.
In WKY rats, vigorous responses to the BCTD, to which
the Lewis rat responded only in the late phase of AA, were
observed very early, 10 d after injection of M. tuberculosis.
These results suggest that T cell responses to the BCTD are
involved in the downregulation of the acute inflammatory
arthritis in the late phase of the disease in AA-susceptible
Lewis rat; similarly, T cell responses to the same determi-
nants initiated soon after injection of M. tuberculosis induce
effective protection against arthritis in WKY rats. The early
and efficient display of the BCTD by M. tuberculosis–immu-
nized WKY rats but not by Lewis rats could be owing to
subtle differences in the processing and presentation of
Bhsp65 by the APC of WKY and Lewis rats, which in turn
could be attributable to the difference in the non-MHC
genes of these two rat strains. However, our results do not
rule out other factors that also might contribute to the AA
resistance of WKY rats, e.g., (a) hormonal and other neu-
rophysiological parameters (45, 46), (b) difference in the
RT.6 locus of WKY and Lewis rats (23, 47, 48), and (c) a
change in the balance of Th1/Th2 induction (49). In most
of the earlier reports on AA, the Fisher F344 rat (RT.1lvl),
which is resistant to AA, has been extensively studied and
used as a control strain for the Lewis rat (14). It has been
reported that the Fisher rat is deficient in generating T cell
responses to the arthritogenic determinant, 180–188, of
Bhsp65 after injection of M. tuberculosis, and thereby is pro-
tected from AA (14). On the contrary, our results show
that AA-resistant WKY rats raise vigorous responses to de-
terminant 180–188 (within peptide 177–191) of Bhsp65
upon challenge with M. tuberculosis. Thus, clearly the im-
munological mechanisms underlying resistance to AA of
Fisher and WKY rats are different. In this regard, study of
AA in WKY rats would offer novel insights into the patho-
genesis and treatment of this disease. Moreover, this rat
strain might also be valuable in studying other animal mod-
els of autoimmune disease like EAE (49a).
AA can be induced in the Lewis rat by injection of M.
tuberculosis; however, the precise autoantigen(s) responsible
for AA are not known. Several candidate autoantigens have
been proposed (13, 50, 51), but there is no direct evidence
so far that any one of these antigens is arthritogenic in
Lewis rats. We (29) and others (52–54) have suggested that
self-hsp65 (Rhsp65) may be a target of T cells primed by
Bhsp65. Based on our earlier study on mouse lysozyme as a
model self-protein (29), we suggested that newly displayed
cryptic determinants within Rhsp65 could serve as targets
of autoimmune reactivity for T cells primed with the cor-
responding dominant determinants within Bhsp65. In addi-
tion, any self-antigenic determinants within the tissue com-
ponents of the joints, with the appropriate cross-reactive
homology with determinants within self-hsp65, could also
serve as targets for the pathogenic T cells. We are currently
characterizing the T cell responses to self-hsp65 to evaluate
their direct role in the pathogenesis of arthritis.
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